Securities · Lawsuit Filed

CVRx Securities Class Action (CVRX): Investors Allege Barostim Sales Growth Hid Improper Practices

Published November 15, 2026

Investors who bought CVRx common stock between July 25, 2023 and August 6, 2026 may be covered by a proposed securities class action alleging CVRx and four current and former executives hid that Barostim sales growth depended in part on improper marketing and payment practices, the subject of a Justice Department investigation the company disclosed in August 2026. No class has been certified and there is nothing to file yet.

Stock market chart for the CVRx securities class action
▼ Allegations Only · No Settlement Yet

This article describes a class action complaint. The statements below are unproven allegations. CVRx has not been found liable, there is no certified class, and nothing to claim at this time. This page is informational and is not legal advice.

What Is This About?

A pension fund filed a proposed securities class action against CVRx, Inc. (NASDAQ: CVRX), the Minneapolis-area maker of the Barostim implant for heart failure, on November 9, 2026. The case is Oklahoma Police Pension and Retirement System v. CVRx, Inc., No. 0:26-cv-04746, in the U.S. District Court for the District of Minnesota, before Judge Eric C. Tostrud. It is brought on behalf of everyone who bought CVRx common stock from July 25, 2023 through August 6, 2026.

The complaint names CVRx; Kevin Hykes, president and CEO since February 2024; Nadim Yared, CEO from 2006 to February 2024; Jared Oasheim, the chief financial officer through 2026; and Robert John, chief revenue officer from June 2024 to August 2026. It asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.

Status Complaint Filed · Nov. 9, 2026 D. Minn. · No. 0:26-cv-04746-ECT-ECW
Lead Plaintiff Deadline January 8, 2027 Class period July 25, 2023 – August 6, 2026
Can I Claim? No — nothing to claim yet No class certified · no settlement

What the Complaint Alleges

The complaint alleges that, throughout the class period, CVRx and its executives failed to tell investors that part of Barostim’s sales growth came from improper marketing of the device, kickbacks and false information given to government health programs, conduct the complaint says could violate the False Claims Act and the Anti-Kickback Statute, which made some of the company’s revenue unsustainable. It also alleges the company told investors its sales-force turnover had stabilized and its sales-force realignment was on track when neither was true. CVRx has not responded to the lawsuit publicly, and the allegations have not been proven.

The August 6, 2026 Disclosure

After the market closed on August 6, 2026, CVRx disclosed in its quarterly report that it had received a civil investigative demand from the U.S. Department of Justice on May 14, 2026. The company described it as a False Claims Act investigation into whether it improperly marketed its device, offered or paid kickbacks, or gave false information to government health insurance programs. CVRx said it was cooperating and had not recorded any liability for the matter. The same day, it cut its 2026 revenue outlook to $58 million to $60 million, citing fewer sales territories and lower sales-force productivity.

CVRx stock fell $3.55, or 60%, from $5.94 to $2.39 the next day, according to the complaint. The complaint also points to earlier declines it ties to the same issues:

Lead Plaintiff Deadline and What Happens Next

Investors who want to ask the court to appoint them lead plaintiff must file by January 8, 2027, 60 days after the first notice of the case was published. The lead plaintiff directs the case for the proposed class; a class member does not need to seek that role to remain part of the class. After a lead plaintiff is appointed, an amended complaint is typically filed and CVRx is expected to move to dismiss. Nothing is payable unless the case later settles or wins and a court approves a claim process.

Questions

Who is covered by the CVRx securities class action?

The proposed class is everyone who bought CVRx common stock between July 25, 2023 and August 6, 2026, inclusive. No class has been certified yet, so the class definition can change.

What is the Justice Department investigating at CVRx?

CVRx disclosed that it received a civil investigative demand from the Justice Department on May 14, 2026, as part of a False Claims Act investigation into whether it improperly marketed its Barostim device, offered or paid kickbacks, or gave false information to government health insurance programs. CVRx said it was cooperating. An investigation is not a finding of wrongdoing.

Is CVRx’s former chief revenue officer a defendant?

Yes. Robert John, who was chief revenue officer from June 2024 until his employment ended on August 10, 2026, is one of four executives named. Some press releases have described him as CEO; the company’s filings say he was chief revenue officer.

Can CVRx investors file a claim now?

No. The case is at the complaint stage. There is no settlement and no claim form. The January 8, 2027 date is the deadline to ask to be lead plaintiff, not a claim deadline.

Sources

This page is informational and is not legal advice.

For more class actions keep scrolling below.
Status Complaint filed
Case Title Oklahoma Police Pension and Retirement System v. CVRx, Inc.
Case Number 0:26-cv-04746-ECT-ECW
Court U.S. District Court, District of Minnesota
Date Filed November 9, 2026
Official Website Court Docket (CourtListener)

More New Securities Class Actions